This study is looking at how ZT-01 affects low blood sugar (hypoglycemia) at night in adults with type 1 diabetes. ZT-01 is thought to work by increasing a hormone called glucagon during low blood sugar, which might help prevent these episodes. We want to see if ZT-01, given as a daily injection, can reduce the number of night-time low blood sugar events and what its effects are on overall blood sugar levels. We will also be checking the safety of ZT-01. You might be able to join if you are 18-75 years old, have had type 1 diabetes for at least 5 years, and experience night-time low blood sugar.

Study design

This interventional study plans to enroll 186 participants. Participants will receive either ZT-01 at different doses (7 mg, 15 mg, or 22 mg) or a placebo (an inactive substance) by daily subcutaneous injection.

What's involved

Participants will wear a continuous glucose monitor (CGM) provided by the study during two 4-week periods. During these periods, they will self-inject the study drug before bed.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome, incidence of nocturnal hypoglycemia, will be measured during each 28-day treatment period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.